within Pharmacolibrary.Drugs.D_Dermatologicals.D06A_AntibioticsForTopicalUse.D06AX01_FusidicAcid;

model FusidicAcid
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.91,
    Cl = 1.111111111111111e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.0107,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006666666666666667,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>FusidicAcid</td></tr><tr><td>ATC code:</td><td>D06AX01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>10.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Fusidic acid is a steroidal antibiotic mainly used to treat skin and soft tissue infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved and widely used in topical, oral, and intravenous formulations, particularly in Europe and some other countries, although it is less commonly used in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Bulitta, JB, et al., &amp; Ambrose, PG (2013). Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. <i>Antimicrobial agents and chemotherapy</i> 57(1) 498–507. DOI:<a href=\"https://doi.org/10.1128/AAC.01354-12\">10.1128/AAC.01354-12</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23147726/\">https://pubmed.ncbi.nlm.nih.gov/23147726</a></p></li><li><p>Marsot, A, et al., &amp; Blin, O (2017). Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. <i>British journal of clinical pharmacology</i> 83(5) 1039–1047. DOI:<a href=\"https://doi.org/10.1111/bcp.13178\">10.1111/bcp.13178</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27813241/\">https://pubmed.ncbi.nlm.nih.gov/27813241</a></p></li><li><p>Marsot, A, et al., &amp; Guilhaumou, R (2020). Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. <i>British journal of clinical pharmacology</i> 86(11) 2319–2324. DOI:<a href=\"https://doi.org/10.1111/bcp.14319\">10.1111/bcp.14319</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32330996/\">https://pubmed.ncbi.nlm.nih.gov/32330996</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D06AX01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end FusidicAcid;
